Skin & cosmetic
Dipeptide Diaminobutyroyl Benzylamide Diacetate
Syn-Ake, SYN-AKE
Syn-Ake is a synthetic tripeptide-like cosmetic ingredient designed to mimic waglerin-1, a component of temple viper venom. It is marketed for expression lines as a topical alternative to botulinum toxin.
Also known as: Syn-Ake, SYNAKE, waglerin mimetic
- Status
- Dipeptide Diaminobutyroyl Benzylamide Diacetate is used as a cosmetic or over-the-counter ingredient, not as an approved drug.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Not applicable — acts locally in skin.
- How it's taken
- Topical, in a leave-on serum or cream
- Mechanism
- Cosmetic / topical
- Pathways
- Neuromuscular Junction
How Dipeptide Diaminobutyroyl Benzylamide Diacetate works
Waglerin-1 is a peptide from Tropidolaemus wagleri venom that antagonises the muscle-type nicotinic acetylcholine receptor. Syn-Ake is a synthetic small molecule designed to reproduce that antagonism, blocking the postsynaptic receptor so acetylcholine cannot trigger contraction. This is postsynaptic blockade, mechanistically distinct from Acetyl Hexapeptide-3 and Pentapeptide-18, which both act presynaptically.
What research has looked at
- It acts at a genuinely different point in neuromuscular transmission from the other topical "botox alternative" peptides, which is a coherent rationale for combining them.
- The parent venom peptide has real, well-characterised nicotinic receptor antagonist activity.
- Manufacturer studies report reductions in wrinkle depth over four to six weeks.
- It is non-invasive and generally well tolerated.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Supporting studies are manufacturer-funded, small and short, and independent replication is essentially absent.
- To work as described it must reach the neuromuscular junction beneath the dermis — a far greater penetration barrier than reaching dermal fibroblasts, and one that has not been demonstrated for this ingredient.
- Effects are far smaller than botulinum toxin, and marketing comparisons are not supported by head-to-head trials.
- Benefits reverse on discontinuation.
- It is a cosmetic ingredient, not a drug, and is not evaluated by the FDA for efficacy.
Sources
- PubMed research on Syn-Ake waglerin nicotinic receptor cosmetic peptide · NIH · National Library of Medicine
- DrugBank record for waglerin · DrugBank
- Active clinical trials for waglerin · U.S. National Library of Medicine
Track Dipeptide Diaminobutyroyl Benzylamide Diacetate in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Dipeptide Diaminobutyroyl Benzylamide Diacetate FAQ
What is Dipeptide Diaminobutyroyl Benzylamide Diacetate?
Syn-Ake is a synthetic tripeptide-like cosmetic ingredient designed to mimic waglerin-1, a component of temple viper venom. It is marketed for expression lines as a topical alternative to botulinum toxin.
How does Dipeptide Diaminobutyroyl Benzylamide Diacetate work?
Waglerin-1 is a peptide from Tropidolaemus wagleri venom that antagonises the muscle-type nicotinic acetylcholine receptor. Syn-Ake is a synthetic small molecule designed to reproduce that antagonism, blocking the postsynaptic receptor so acetylcholine cannot trigger contraction. This is postsynaptic blockade, mechanistically distinct from Acetyl Hexapeptide-3 and Pentapeptide-18, which both act presynaptically.
Is Dipeptide Diaminobutyroyl Benzylamide Diacetate FDA approved?
No. Dipeptide Diaminobutyroyl Benzylamide Diacetate is used as a cosmetic or over-the-counter ingredient, not as an approved drug. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Dipeptide Diaminobutyroyl Benzylamide Diacetate?
Reported half-life: Not applicable — acts locally in skin.
How is Dipeptide Diaminobutyroyl Benzylamide Diacetate taken?
Topical, in a leave-on serum or cream.
What side effects have been reported with Dipeptide Diaminobutyroyl Benzylamide Diacetate?
Reported in the sources: Supporting studies are manufacturer-funded, small and short, and independent replication is essentially absent; To work as described it must reach the neuromuscular junction beneath the dermis — a far greater penetration barrier than reaching dermal fibroblasts, and one that has not been demonstrated for this ingredient; Effects are far smaller than botulinum toxin, and marketing comparisons are not supported by head-to-head trials; Benefits reverse on discontinuation; It is a cosmetic ingredient, not a drug, and is not evaluated by the FDA for efficacy.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.